Sunday, September 27, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 17, 2026

Top Analyst Reports for AbbVie, RTX & IBM

View original at finance.yahoo.com
Top Analyst Reports for AbbVie, RTX & IBM Tuesday, February 17, 2026 The Zacks Research Daily presents the best research output of our analyst team…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rising expenses remain a concern for Affirm

    80% confidence
  • Rocky Mountain faces near-term liquidity and covenant risk, with $0.6 million cash, continued operating losses, high-cost 12% debt and reliance on external funding

    80% confidence
  • LATAM Airlines is focused on premium traffic and an efficient cost structure

    80% confidence
  • IPG Photonics is benefiting from innovations such as the CROSSBOW laser counter-UAV system and growth in medical applications, particularly urology

    80% confidence
  • Spectrum Brands is focused on driving growth through brand-building, innovation and operating efficiency

    80% confidence
  • EVI's fiscal 2025 acquisitions contributed $40 million in revenues and $2 million in net income year to date

    80% confidence
  • Supply-chain challenges continue to affect the aerospace sector, which may adversely impact RTX

    80% confidence
  • IBM's focus on quantum technology for solutions to complex problems beyond the reach of classical computing is a tailwind

    80% confidence
  • AbbVie has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq

    80% confidence
  • DaVita's patient-centric care model leverages its platform and continued execution of targeted initiatives to improve treatment adherence is an added plus

    80% confidence
  • AbbVie has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth

    80% confidence
  • The uncertainties created by the recent imposition of U.S. government-issued import tariffs pose a risk for RTX

    80% confidence
  • EVI's operating cash flow improved to $5.1 million despite a $12.6 million inventory build

    80% confidence
  • Strong volumes and a favorable mix across large commercial engines and Pratt Canada operations are expected to support RTX's growth momentum in the commercial aerospace market

    80% confidence
  • AbbVie delivered robust net sales growth in 2025 which is just the second full year following the Humira LOE in the United States

    80% confidence
  • Growth in Affirm's active merchant numbers and improvement in Gross Merchandise Value will fuel its top-line

    80% confidence
  • Weakness in IBM's traditional business and foreign exchange volatility remain concerns

    80% confidence
  • Corcept's sole dependence on Cushing's syndrome drug, Korlym, for revenues is concerning

    80% confidence
  • Improved mix, pricing discipline and operating leverage are enhancing EVI's earnings quality

    80% confidence
  • Rocky Mountain is working on margin-first execution which is driving structural recovery with manufacturing gross margin rising to 21.4% from 10%

    80% confidence
  • EVI's earnings conversion remains pressured with net income dipping to $4.2 million as SG&A rose 26%, outpacing revenue growth

    80% confidence
  • Check Point is gaining from solid contributions of its growth-oriented products, primarily CloudGuard, Sandblast Zero-day threat prevention and Infinity solutions

    80% confidence
  • Boise Cascade is hurting due to slow single-family housing starts, resulting in low volumes and unfavorable commodity pricing

    80% confidence
  • IBM is gaining traction on the Watsonx platform, which is likely to be its core technology platform for AI capabilities

    80% confidence
  • Steadily improving global commercial air traffic boosts RTX's sales

    80% confidence
  • Skyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years

    80% confidence
  • Strong service and parts growth support Penske's earnings, though declining BEV units and softer premium demand may limit near-term results

    80% confidence
  • AbbVie's neuroscience portfolio is contributing to top-line growth

    80% confidence
  • Easing demand momentum amid persistent headwinds hurts Shake Shack with limited traffic growth, inflation pressures and weather disruptions remaining a concern

    80% confidence
  • IBM's acquisition spree has escalated integration risks, while its high debt level is burdensome

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Top Analyst Reports for AbbVie, RTX & IBM — Source | Via News | Via News